Pharma Focus Asia
KP - Sustainable Packaging Solutions

GSK to invest £200m in UK

Introduction:

With an effort of strengthening its services, Glaxo Smith Kline has announced a series of investments in the UK that approximately sum up to £200 million. These investments will support the company's production of antibiotic medicine and create a centre for pharmaceutical manufacturing innovation in the UK.

GSK also plans to set up a new facility that's dedicated to yoke innovative technologies with the prospective ability to transform the methods of manufacturing medicines.

New equipment and machinery will be updated in manufacturing units in Hertfordshire and Worthing Ware and Sussex.

Location:

The tentative preferred site for GSK's new centre is Ware, Hertfordshire (GSK already has manufacturing and R&D facilities here).

Features:

The new manufacturing facilities in Ware will be used to build and develop GSK's newest generation of inhaler devices (RelvarTM ElliptaTM inhaler) for respiratory diseases.

In Worthing, a new bulk sterile building and filling line will be built for the company's antibiotic medicine AugmentinTM, which is exported to 150 countries. A new centre for manufacturing innovation will be built, dedicated to transforming emerging science and technologies into practical manufacturing applications.

The technologies used in these centres use nano-technologies to create intelligent drug product formulations which minimise side-effects and enhance efficacy.

Investment:

GSK had announced a £500 million last March that included building a new factory in Ulverston, Cumbria. This investment of £200 m is in addition to the earlier investment.

GSK also recently announced an investment of £25 million to expand its operations in Montrose to support the delivery of its new pipeline of medicines.

Specifications Table

  • Project Name
  • GSK to invest £200m in UK
  • Location
  • Ware, Hertfordshire and Worthing, Sussex
  • Commence
  • Jan 2014
  • Expected date of completion
  • N/A
  • Estimated investment
  • 200million
  • Key players
  • GSK
Latest Issue
Get instant
access to our latest e-book
Standard BioTools™MFA + MMA 2024Gibco Adherent Kidney Media PanelAsia Healthcare Week 2024Equinix accelerated medical research...CPHI Korea 2024CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024
Searching for an end-to-end patient tech solution?